February 25, 2020 10:27 AM ESTUpdated February 26, 06:36 AM
FDA+

In fi­nal re­port, ICER ap­pears to have a change of heart on new acute mi­graine ther­a­pies

Natalie Grover

Reporter

ICER ap­pears to have re­versed course on its as­sess­ment of two acute mi­graine ther­a­pies.

The cost-ef­fec­tive­ness watch­dog in No­vem­ber is­sued a draft re­port sug­gest­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

A service from the Financial Times